Neoadjuvant Osimertinib in the Perioperative Setting for Resectable, EGFR-Mutated NSCLC

1. Osimertinib is recommended for neoadjuvant treatment in resectable EGFR-mutated NSCLC. 2. The NeoADAURA trial showed improved major pathologic response rates. 3. Surgery completion rates were high across treatment groups. 4. Adverse events during neoadjuvant treatment were largely mild. 5. Future research is needed to refine treatment for better outcomes.